《全國(guó)職稱(chēng)英語(yǔ)考試 衛(wèi)生類(lèi)B級(jí) 閱讀與完形填空押題【孫、王、李三個(gè)王牌老師綜合而來(lái)】》由會(huì)員分享，可在線閱讀，更多相關(guān)《全國(guó)職稱(chēng)英語(yǔ)考試 衛(wèi)生類(lèi)B級(jí) 閱讀與完形填空押題【孫、王、李三個(gè)王牌老師綜合而來(lái)】（4頁(yè)珍藏版）》請(qǐng)?jiān)谘b配圖網(wǎng)上搜索。
1、Once daily pill could simplify HIV treatment
Beistol-Myers squibb and Gilead Sciences have combined many HIV drugs into a single pill. Sometimes the best medicine is moer than one kind of medicine. Maiaria,tuberculosis and HIV/AIDS, for example, are all treated with combinations of drugs. But that
2、can mean a lot of pills to take. It would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .
Now, two companies say they have done that foe people just starting treatment for HIV, the virus that causes AIDS. The companies are Bristol-Myers Squibb and
3、 Gilead Sciences. They have developed a single pill that combines three drugs currently on the market . Bristol-Myers Squibb sells one of them under the name of Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.
Combining drugs involeves more than tech
4、nical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of HIV.
In January the New England Journal of Medicine published a study o
5、f the new pill . Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed HIV levels in more patients and with fewer side effects. Gil
6、ead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the reaearch . he is paid adviser to Gilead ang Bristol-Meyers Squibb as well as the maker of Combivir, Glaxo Smith Kline.
Glaxo Smith Kline reacted to the findings by saying that a
7、single study is of limited value. It says the effectiveness of Combivir has been shown in each of more the fifty studies.
The price of the new once-daily pill has not beet announced. But Gilead ang Bristol-Myers Squibb say they will provide it at reduced cost to developing countries. They plan in t
8、he next few months to ask the United States Food and Drug Administration to approve the new pill.
There are limits to who could take it because of the different drugs it contains.For example pregnant women are told not to take Sustiva because of the risk of birth disorders.Experts say more than f
9、orty million people around the world are living with HIV.
Once daily pill could simplify HIV treatment
Beistol-Myers squibb and Gilead Sciences have combined many HIV drugs into a single pill. Sometimes the best medicine is moer than one kind of medicine. Maiaria,tuberculosis and HIV/AIDS, for
10、 example, are all treated with combinations of drugs. But that can mean a lot of pills to take. It would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .
Now, two companies say they have done that foe people just starting treatment for HIV, the vir
11、us that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences. They have developed a single pill that combines three drugs currently on the market . Bristol-Myers Squibb sells one of them under the name of Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill
12、in two thousand four.
Combining drugs involeves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of HIV.
In
13、January the New England Journal of Medicine published a study of the new pill . Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppress
14、ed HIV levels in more patients and with fewer side effects. Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the reaearch . he is paid adviser to Gilead ang Bristol-Meyers Squibb as well as the maker of Combivir, Glaxo Smith Kline.
15、
Glaxo Smith Kline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more the fifty studies.
The price of the new once-daily pill has not beet announced. But Gilead ang Bristol-Myers Squibb say they will pro
16、vide it at reduced cost to developing countries. They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.
There are limits to who could take it because of the different drugs it contains.For example pregnant women are told not to take Sustiva
17、 because of the risk of birth disorders.Experts say more than forty million people around the world are living with HIV.
Once daily pill could simplify HIV treatment
Beistol-Myers squibb and Gilead Sciences have combined many HIV drugs into a single pill. Sometimes the best medicine is moer th
18、an one kind of medicine. Maiaria,tuberculosis and HIV/AIDS, for example, are all treated with combinations of drugs. But that can mean a lot of pills to take. It would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .
Now, two companies say they hav
19、e done that foe people just starting treatment for HIV, the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences. They have developed a single pill that combines three drugs currently on the market . Bristol-Myers Squibb sells one of them under the name of Sustiva. Gile
20、ad combined the others, Emtriva and Viread, into a single pill in two thousand four.
Combining drugs involeves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joi
21、nt venture agreement of its kind in the treatment of HIV.
In January the New England Journal of Medicine published a study of the new pill . Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The research
22、ers say that after one year of treatment, the new pill suppressed HIV levels in more patients and with fewer side effects. Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the reaearch . he is paid adviser to Gilead ang Bristol-Mey
23、ers Squibb as well as the maker of Combivir, Glaxo Smith Kline.
Glaxo Smith Kline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more the fifty studies.
The price of the new once-daily pill has not beet a
24、nnounced. But Gilead ang Bristol-Myers Squibb say they will provide it at reduced cost to developing countries. They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.
There are limits to who could take it because of the different drugs it c
25、ontains.For example pregnant women are told not to take Sustiva because of the risk of birth disorders.Experts say more than forty million people around the world are living with HIV.
Once daily pill could simplify HIV treatment
Beistol-Myers squibb and Gilead Sciences have combined many HIV d
26、rugs into a single pill. Sometimes the best medicine is moer than one kind of medicine. Maiaria,tuberculosis and HIV/AIDS, for example, are all treated with combinations of drugs. But that can mean a lot of pills to take. It would be simpler if deug companies combined all the medicines into a single
27、 pill, taken just once a day .
Now, two companies say they have done that foe people just starting treatment for HIV, the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences. They have developed a single pill that combines three drugs currently on the market . Bristol
28、-Myers Squibb sells one of them under the name of Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.
Combining drugs involeves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once
29、-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of HIV.
In January the New England Journal of Medicine published a study of the new pill . Researchers compared its effectiveness to that of the widely used combination of Sustiva and C
30、ombivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed HIV levels in more patients and with fewer side effects. Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland,
31、led the reaearch . he is paid adviser to Gilead ang Bristol-Meyers Squibb as well as the maker of Combivir, Glaxo Smith Kline.
Glaxo Smith Kline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more the fift
32、y studies.
The price of the new once-daily pill has not beet announced. But Gilead ang Bristol-Myers Squibb say they will provide it at reduced cost to developing countries. They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.
There are
33、limits to who could take it because of the different drugs it contains.For example pregnant women are told not to take Sustiva because of the risk of birth disorders.Experts say more than forty million people around the world are living with HIV.
The Case of the Disappearing Fingerprints
One
34、 useful anti-cancer drug can effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.Losing them could become troublesome.A case released online in a letter by Annals of Oncology indicates how big a problem of losing.
Eng-Huat Tan,a Singapore-ba
35、sed medical doctor describes a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.After three years on the drug,the patient decided to visit U.S. relatives last Decembr.But he was stopped by U.S. customs officials for 4 hours after entering the country when those officials
36、couldn’t get fingerprints from the man.There were no distinctive swirly marks appearing from his index finger.
U.S.customs has been fingerprinting incoming foreign visitors for years,Tan says.Theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terror
37、ists and potential criminals that our federal guardians have been tasked with keeping out of the country,Unfortunately,for the Singaporean traveler,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pads.Hence,no fingerprints.
“It is uncertain when fingerpr
38、int loss will begin to take place in patients who are taking capecitabine,” Tan points out. So he cautions any physicians who prescribe the drug to provide their patients with a doctor’s note pointing out that their medicine may cause fingerprints to disappear.
Eventually,the Singapore traveler m
39、ade it into the United States. I guess the name on his passport didn’t raise any red flags.But he’s also now got the explanatory doctor’s note-and won’t leave home without it.
By the way,maybe the Food and Drug Administration,which approved use of the drug 11 years ago,should consider updating it
40、s list of side effects associated with this medicine.The current list does note that patients may experience vomiting,stomach pain and some other side effects. But no where does it mention the potential for loss of fingerprints.
The Case of the Disappearing Fingerprints
One useful anti
41、-cancer drug can effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.Losing them could become troublesome.A case released online in a letter by Annals of Oncology indicates how big a problem of losing.
Eng-Huat Tan,a Singapore-based medical
42、doctor describes a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.After three years on the drug,the patient decided to visit U.S. relatives last Decembr.But he was stopped by U.S. customs officials for 4 hours after entering the country when those officials couldn’t get
43、 fingerprints from the man.There were no distinctive swirly marks appearing from his index finger.
U.S.customs has been fingerprinting incoming foreign visitors for years,Tan says.Theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terrorists and pot
44、ential criminals that our federal guardians have been tasked with keeping out of the country,Unfortunately,for the Singaporean traveler,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pads.Hence,no fingerprints.
“It is uncertain when fingerprint loss wil
45、l begin to take place in patients who are taking capecitabine,” Tan points out. So he cautions any physicians who prescribe the drug to provide their patients with a doctor’s note pointing out that their medicine may cause fingerprints to disappear.
Eventually,the Singapore traveler made it into
46、the United States. I guess the name on his passport didn’t raise any red flags.But he’s also now got the explanatory doctor’s note-and won’t leave home without it.
By the way,maybe the Food and Drug Administration,which approved use of the drug 11 years ago,should consider updating its list of si
47、de effects associated with this medicine.The current list does note that patients may experience vomiting,stomach pain and some other side effects. But no where does it mention the potential for loss of fingerprints.
The Case of the Disappearing Fingerprints
One useful anti-can
48、cer drug can effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.Losing them could become troublesome.A case released online in a letter by Annals of Oncology indicates how big a problem of losing.
Eng-Huat Tan,a Singapore-based medical doct
49、or describes a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.After three years on the drug,the patient decided to visit U.S. relatives last Decembr.But he was stopped by U.S. customs officials for 4 hours after entering the country when those officials couldn’t get fin
50、gerprints from the man.There were no distinctive swirly marks appearing from his index finger.
U.S.customs has been fingerprinting incoming foreign visitors for years,Tan says.Theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terrorists and potenti
51、al criminals that our federal guardians have been tasked with keeping out of the country,Unfortunately,for the Singaporean traveler,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pads.Hence,no fingerprints.
“It is uncertain when fingerprint loss will be
52、gin to take place in patients who are taking capecitabine,” Tan points out. So he cautions any physicians who prescribe the drug to provide their patients with a doctor’s note pointing out that their medicine may cause fingerprints to disappear.
Eventually,the Singapore traveler made it into the
53、United States. I guess the name on his passport didn’t raise any red flags.But he’s also now got the explanatory doctor’s note-and won’t leave home without it.
By the way,maybe the Food and Drug Administration,which approved use of the drug 11 years ago,should consider updating its list of side e
54、ffects associated with this medicine.The current list does note that patients may experience vomiting,stomach pain and some other side effects. But no where does it mention the potential for loss of fingerprints.
The Case of the Disappearing Fingerprints
One useful anti-cancer drug can
55、 effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.Losing them could become troublesome.A case released online in a letter by Annals of Oncology indicates how big a problem of losing.
Eng-Huat Tan,a Singapore-based medical doctor describes
56、 a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.After three years on the drug,the patient decided to visit U.S. relatives last Decembr.But he was stopped by U.S. customs officials for 4 hours after entering the country when those officials couldn’t get fingerprints fr
57、om the man.There were no distinctive swirly marks appearing from his index finger.
U.S.customs has been fingerprinting incoming foreign visitors for years,Tan says.Theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terrorists and potential criminals
58、 that our federal guardians have been tasked with keeping out of the country,Unfortunately,for the Singaporean traveler,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pads.Hence,no fingerprints.
“It is uncertain when fingerprint loss will begin to take
59、place in patients who are taking capecitabine,” Tan points out. So he cautions any physicians who prescribe the drug to provide their patients with a doctor’s note pointing out that their medicine may cause fingerprints to disappear.
Eventually,the Singapore traveler made it into the United State
60、s. I guess the name on his passport didn’t raise any red flags.But he’s also now got the explanatory doctor’s note-and won’t leave home without it.
By the way,maybe the Food and Drug Administration,which approved use of the drug 11 years ago,should consider updating its list of side effects assoc
61、iated with this medicine.The current list does note that patients may experience vomiting,stomach pain and some other side effects. But no where does it mention the potential for loss of fingerprints.
Hospital Mistreatment
According to a study,mose medical interns report exp
62、eriencing mistreatment,including humiliation by senior doctors,being threatened,or physical abuse in their first year out of medical school.
The findings come from analysis of the responses to a 13-page survey mailed in January 1991 to 1,733 second-year residents. The survey and analysis appear i
63、n the April 15th issue of the Journal of the American Medical Association.
Overall,out of the 1,277 residents who completed surveys,1,185,said that they had experienced at least one incident of mistreatment in their intern year In addition to reporting incidents where they were abused,more than 4
64、5% of the residents said they had witnessed at least one incident where other persons had made false medical redcords.Moreover,nearly three quarters of the residents said they had witnessed mistreatment of patients by other residents,attending physicians,or nurses,Almost 40% said patient mistreatmen
65、t was a frequent event.
More than 10% of the residents said they were not allowed to have enough sleep,and the average number of hours without sleep was 37.6. The average on-call time during a typical week was 56.9 hours,but about 25% of the residents said their on-call assignments were more than
66、 80 hours some weeks.
Although 30% of the residents said they experienced some type of sexual harassment of discrimination,verbal abuse was the most common problem cited.When abusive incidents were limited to events occurring three or more times,53% of the respondedts reported that they were belittled of humiliated by more senior residents,while just over 21% reported someone taking credit for their work.Being “given tasks for punishment,” “being pushed,kicked or hit ,”and having someone “thr
全國(guó)職稱(chēng)英語(yǔ)考試 衛(wèi)生類(lèi)B級(jí) 閱讀與完形填空押題【孫、王、李三個(gè)王牌老師綜合而來(lái)】
